aTYR PHARMA (ATYR) EBIAT (2019 - 2025)
aTYR PHARMA (ATYR) has disclosed EBIAT for 7 consecutive years, with -$14.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 6.75% year-over-year to -$14.0 million, compared with a TTM value of -$74.1 million through Dec 2025, down 15.79%, and an annual FY2025 reading of -$74.1 million, down 15.77% over the prior year.
- EBIAT was -$14.0 million for Q4 2025 at aTYR PHARMA, up from -$25.8 million in the prior quarter.
- Across five years, EBIAT topped out at -$7.2 million in Q1 2021 and bottomed at -$25.8 million in Q3 2025.
- Average EBIAT over 5 years is -$13.4 million, with a median of -$12.8 million recorded in 2022.
- The sharpest move saw EBIAT plummeted 508.39% in 2021, then rose 14.38% in 2023.
- Year by year, EBIAT stood at -$8.6 million in 2021, then rose by 12.18% to -$7.5 million in 2022, then plummeted by 96.24% to -$14.8 million in 2023, then fell by 1.46% to -$15.0 million in 2024, then increased by 6.75% to -$14.0 million in 2025.
- Business Quant data shows EBIAT for ATYR at -$14.0 million in Q4 2025, -$25.8 million in Q3 2025, and -$19.5 million in Q2 2025.